Antibiotics Surveillance Program: Survey on the Resistance Patterns of Microorganisms to Antibiotics in Nosocomial Infections. by Sheril, K C
  
 
 
 
 
ANTIBIOTICS SURVEILLANCE PROGRAM: SURVEY ON THE 
RESISTANCE PATTERNS OF MICROORGANISMS TO 
ANTIBIOTICS IN NOSOCOMIAL INFECTIONS 
 
Dissertation Submitted to 
The Tamil Nadu Dr. M.G.R Medical University, Chennai 
In partial fulfillment for the requirement of the Degree of 
 
MASTER OF PHARMACY 
(Pharmacy Practice) 
 
Submitted by: 
    Reg No. 26107290 
APRIL 2012 
 
 
 
Department of Pharmacy Practice 
KMCH COLLEGE OF PHARMACY 
KOVAI ESTATE, KALAPATTI ROAD, 
COIMBATORE-641 048. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Certificates 
  
 
 
Dr. A. Rajasekaran, M.Pharm., Ph.D 
Principal, 
KMCH College of Pharmacy, 
Kovai Estate, Kalappatti Road, 
Coimbatore - 641 048. (T.N) 
 
 
 
CERTIFICATE 
 
This is to certify that the dissertation work entitled “ANTIBIOTICS 
SURVEILLANCE PROGRAM: SURVEY ON THE RESISTANCE 
PATTERNS OF MICROORGANISMS TO ANTIBIOTICS IN 
NOSOCOMIAL INFECTIONS” submitted by Mr. Sheril K.C, is a bonafide 
work carried out by the candidate under the guidance of Mr. K. Chandrasekaran 
M. Pharm., and submitted to the Tamil Nadu Dr. M.G.R. Medical University, 
Chennai, in partial fulfillment for the Degree of Master of Pharmacy in 
Pharmacy Practice at the Department of Pharmacy Practice, KMCH College of 
Pharmacy, Coimbatore, during the academic year 2010-2012. 
 
 
 
 
 
 Dr. A. Rajasekaran, M.Pharm., Ph.D 
                                   Principal 
 
 
  
 
 
K Chandrasekaran, M. Pharm., 
Asst. Professor & Clinical Pharmacist, 
Department of Pharmacy Practice, 
KMCH College of Pharmacy 
Coimbatore. 
 
 
 
CERTIFICATE 
 
This is to certify that the dissertation work entitled “ANTIBIOTICS 
SURVEILLANCE PROGRAM: SURVEY ON THE RESISTANCE 
PATTERNS OF MICROORGANISMS TO ANTIBIOTICS IN 
NOSOCOMIAL INFECTIONS” submitted by Mr. Sheril K.C, to the Tamil 
Nadu  Dr. M.G.R. Medical University, Chennai, in partial fulfillment  for the 
Degree of Master of Pharmacy in Pharmacy Practice is a bonafide work carried 
out by the candidate under my guidance at the Department of Pharmacy Practice, 
KMCH College of Pharmacy, Coimbatore, during the academic year 2010-2012. 
 
 
 
 
  K Chandrasekaran, M. Pharm., 
 Assistant Professor & Clinical Pharmacist. 
 
 
 
 
 
  
 
 
                 
DECLARATION 
 
I do hereby declare that the dissertation work entitled “ANTIBIOTICS 
SURVEILLANCE PROGRAM: SURVEY ON THE RESISTANCE 
PATTERNS OF MICROORGANISMS TO ANTIBIOTICS IN 
NOSOCOMIAL INFECTIONS” submitted to the Tamil Nadu Dr. M.G.R. 
Medical University, Chennai, in partial fulfillment for the Degree of Master of 
Pharmacy in   Pharmacy Practice, was done by me under the guidance of Mr. K. 
Chandrasekaran, M.Pharm., at the Department of Pharmacy Practice, KMCH 
College of Pharmacy, Coimbatore, during the academic year 2010-2012. 
 
 
 
 
                                                                                            SHERIL KC 
 
 
  
 
 
 
EVALUATION CERTIFICATE 
 
This is to certify that the dissertation work entitled “ANTIBIOTICS 
SURVEILLANCE PROGRAM: SURVEY ON THE RESISTANCE 
PATTERNS OF MICROORGANISMS TO ANTIBIOTICS IN 
NOSOCOMIAL INFECTIONS” submitted by Mr. Sheril K.C, Reg. No: 
26107290 to the Tamil Nadu Dr. M.G.R. Medical University, Chennai in partial 
fulfillment for the Degree of Master of Pharmacy in Pharmacy Practice is a 
bonafide work carried out by the candidate at the Department of Pharmacy 
Practice, KMCH College of Pharmacy, Coimbatore and was evaluated by us during 
the academic year 2010-2012. 
 
 
Examination Center:  KMCH College of Pharmacy, Coimbatore. 
Date:  
 
 
 
Internal Examiner                                                         External Examiner 
 
 
Convener of Examinations 
 
  
ACKNOWLEDGEMENT 
I pay obeisance to the Almighty for blessing me with all the confidence, courage, 
Inspiration, and curiosity to complete this project. 
It is my privilege to submit my deepest sense of gratitude and respectful regard to my 
beloved Guide Mr. K. Chandrasekaran M.Pharm., Assistant Professor & Clinical 
Pharmacist, Department of Pharmacy practice, KMCH College of Pharmacy, 
Coimbatore, for his excellent guidance, constant encouragement and inspiration given 
throughout the tenure of the dissertation work. 
I express my sincere thanks and gratitude to my Principal, Dr. A. Rajasekaran, 
M.Pharm., Ph.D   KMCH College of Pharmacy for providing me with a cooperative 
and creative environment to work excellently. 
I am overwhelmed by the generous help, and enthusiastic encouragement offered by   
Dr. P. Chinnaswami, Ph.D, M.Sc, FICS, MAACC, FIFCC (Clinical chemistry), 
Medical Laboratory, KMCH. 
I express my sincere thanks to Mr. D. Gandhiraj, M.Sc, Med, (Micro) Microbiology 
Department, KMCH, and all the staffs of Microbiology Department for their help and 
co-operation. 
I take this opportunity to acknowledge the help extended to me by the Medical 
Records Department of KMCH without whose timely assistance, the data collection 
would not have been possible. 
 
  
My heartfelt thanks to my Lecturers, Dr. SUCHANDRA SEN, M.Pharm., Ph.D., A. 
VIJAYAKUMAR, M.Pharm., Mr. V. SIVAKUMAR, M.Pharm., Mr. S. 
PALANISWAMY, M.Pharm., (Ph.D)., Mrs. K. GEETHA, M.Pharm., (Ph.D)., 
Mr. C. DANDAPANI, M.Pharm., and all other teaching and non-teaching staffs for 
their encouraging suggestions and judicious help. 
I extend my sincere thanks to our beloved chairman Dr. Nalla. G. Palaniswami MD., 
AB (USA)., and Madam Trustee Dr. Thavamani D. Palaniswami, MD., of Kovai 
Medical Center Research and Educational Trust, Coimbatore for providing me 
with all the facilities to carry out a work of this kind in a corporate hospital. 
I am deeply obliged with warm gratitude towards my Mom, Shelin and Sherun for 
their faith in me and for the prayers they have offered for me for the completion of this 
project work in a fruitful manner. 
It’s my privilege to express my deep sense of gratitude and love to all my dear 
classmates, seniors, juniors and friends for their memorable company and 
encouragement. 
Last but not the least, I thank one and all who are directly or indirectly involved in this 
study and the Almighty to complete this herculean task successfully. 
 
                                                                
    SHERIL KC 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
  
 
 
  
LIST OF ABBREVIATIONS 
                                                                                                                             
 
  AMR  -  Antimicrobial Resistance 
  BSI  - Blood Stream Infections  
  BW  - Birth Weight 
  CAP  - Community Acquired Pneumonia  
  CAUTIs - Catheter Associated Urinary Tract Infections 
  CDC  - Center for Disease Control and Prevention 
  EARSS - European Antimicrobial Resistance Surveillance  
     System 
  HAI  - Hospital Acquired Infections 
  HCAP  - Health Care Associated Pneumonia 
  ICU  - Intensive Care Unit 
  MDR-TB - Multi Drug Resistant Tuberculosis 
  MLST  - Multi Locus Sequence Typing 
  MRSA  - Methicillin Resistant Staphylococcus Aureus  
  NDM-1 - New Delhi Metallo beta lactamase 
  NICU  - Neonatal Intensive Care Unit 
  NIs  - Nosocomial Infections  
  NNIS  - National Nosocomial Infection Surveillance 
  PABA  - Para Amino Benzoic Acid 
  PBP  - Penicillin Binding Protien 
  
 
 
  pBSI  - Primary Blood Stream Infection 
  PDR  - Potentially Drug Resistance  
  PFGE  - Pulsed Field Gel Electrophoresis 
  RICU  - Respiratory Intensive Care Unit 
  SICU  - Surgical Intensive Care Unit 
  SOFA  - Sepsis Related Organ Failure Assessment 
  SSTI  - Skin and Soft Tissue Infections 
  TBSAB - Total Body Surface Area Burn 
  VRE  - Vancomycin Resistant Enterococci 
  WHO  - World Health Organization 
  XDR-TB - Extensively Drug Resistant Tuberculosis 
 
 
 
 
 
 INDEX 
 
 
 
S.No CONTENTS 
PAGE 
No. 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
7 
 
8. 
 
9 
 
10 
 
INTRODUCTION 
 
REVIEW OF LITERATURE 
 
AIM AND OBJECTIVES 
 
PLAN OF STUDY 
 
METHODOLOGY 
 
RESULTS AND DISCUSSION 
 
TABLES & GRAPHS 
 
SUMMARY AND CONCLUSION 
 
BIBLIOGRAPHY 
 
ANNEXURES 
Annexure I : Permission letter from Hospital Authority 
Annexure II : Permission letter from Ethics Committee 
Annexure III : Patient Data Collection Form 
 
1 
 
10 
 
28 
 
29 
 
30 
 
34 
 
39 
 
54 
 
57 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
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INTRODUCTION 
The emergence of resistance to antimicrobial agents is a global public 
health problem, particularly in pathogens causing nosocomial infections. 
Antimicrobial resistance results in increased illness, deaths, and health-care costs. 
The distribution of pathogens causing nosocomial infections, especially 
antimicrobial-resistant pathogens, changes with time and varies among hospitals 
and among different locations in the same hospital.
1
  
The increasing number of immunocompromised patients and increased use 
of indwelling devices, as well as widespread use of antimicrobial agents in hospital 
settings, particularly in intensive care units (ICUs), contributes to antimicrobial 
resistance among pathogens causing nosocomial infections. 
ANTIMICROBIAL RESISTANCE (AMR):  
AMR is the expression of the ability of microbes to resist the actions of 
naturally occurring or synthetically produced compounds inimical to their 
survival. In a clinical context, AMR refers to a reduction in clinical efficacy so that 
either the benefits for the individual of treatment with an antimicrobial drug or the 
benefits to general public health are compromised. (WHO)
2 
CAUSE: 
 Inadequate national commitment to a comprehensive and coordinated 
response, ill defined accountability and insufficient engagement of 
communities; 
 Weak or absent surveillance and monitoring systems; 
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 Inadequate systems to ensure quality and uninterrupted supply of medicines 
 Inappropriate and irrational use of medicines, including in animal 
husbandry: 
 Poor infection prevention and control practices; 
 Depleted arsenals of diagnostics, medicines and vaccines as well as 
insufficient research and development on new products.
3
 
An important cause of increasing antibiotic resistance is the selection of 
resistant bacterial strains by mutation and transfer of mobile resistance genes as a 
result of excessive antibiotic prescribing by hospital doctors. Increasing antibiotic 
resistance also caused by transmission of resistant bacteria within hospitals by 
cross colonization of patients via the hands of health care staff and subsequent 
spread between hospitals by transfer of colonized patients. 
The use of antimicrobial agents is a powerful selective force that promotes 
the emergence of resistant strains. Thereby, the growth of antimicrobial resistance 
led a signal to reduce unnecessary antibiotic use and to improve treatment 
protocols to maximize the lifespan of these drugs. To reduce antimicrobial 
resistance, multiple and often conflicting recommendations have been made, which 
includes reduction of all antimicrobial classes, increased use of prophylactic 
antimicrobials to reduce colonization, rotation of different antibiotic classes in a 
temporal sequence, and simultaneous use of different antimicrobials for different 
patients. 
Strategies to control antibiotic resistance in hospitals include 
multidisciplinary cooperation in implementing local policies on use of antibiotics 
and infection control measures, timely detection and reporting of the antibiotic 
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resistant strains, improved surveillance, and aggressive control of transmission of 
epidemic resistant bacteria. 
MECHANISM: 
The four main mechanisms by which microorganisms exhibit resistance to 
antimicrobials are: 
1. Drug inactivation or modification: for example, enzymatic deactivation 
of penicillin G in some penicillin-resistant bacteria through the production 
of β-lactamases 
2. Alteration of target site: for example, alteration of PBP—the binding target 
site of penicillins in MRSA and other penicillin-resistant bacteria 
3. Alteration of metabolic pathway: for example, some sulfonamide-resistant 
bacteria do not require para-aminobenzoic acid (PABA), an important 
precursor for the synthesis of folic acid and nucleic acids in bacteria 
inhibited by sulfonamides, instead, like mammalian cells, they turn to 
using preformed folic acid. 
4. Reduced drug accumulation: by decreasing drug permeability and/or 
increasing active efflux (pumping out) of the drugs across the cell surface.
4
 
SOME FACTS ABOUT AMR: 
About 440000 new cases of multidrug-resistant tuberculosis (MDR-TB) 
emerge annually, causing at least 150000 deaths. Extensively drug-resistant 
tuberculosis (XDR-TB) has been reported in 64 countries.
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Resistance to earlier generation antimalarial medicines such as chloroquine 
and sulfadoxine-pyrimethamine is widespread in most malaria-endemic countries. 
Falciparum malaria parasites resistant to artemisinins are emerging in South-East 
Asia; infections show delayed clearance after the start of treatment (indicating 
resistance). 
A high percentage of hospital-acquired infections are caused by highly 
resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant enterococci. 
New resistance mechanisms, such as the beta-lactamase NDM-1, have 
emerged among several gram-negative bacilli. This can render powerful 
antibiotics, which are often the last defense against multi-resistant strains of 
bacteria, ineffective.
5 
“Antimicrobial Resistance” chosen as World health day (April 7th) 2011 theme by 
WHO
6 
The three key, inter-related elements of the Strategy to control AMR are: 
 Surveillance:  to monitor “how we are doing” and provide the data on 
resistant organisms, illness due to them and antimicrobial usage 
necessary to inform action; 
 Prudent antimicrobial use:  to reduce the pressure for resistance by 
reducing unnecessary and inappropriate exposure of micro-organisms to 
antimicrobial agents in clinical practice, veterinary practice, animal 
husbandry, agriculture and horticulture. 
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 Infection control:  to reduce the spread of infection in general (and thus 
some of the need for antimicrobial agents) and of antimicrobial resistant 
micro-organisms in particular. 
NOSOCOMIAL INFECTIONS: 
An infection acquired in hospital by a patient who was admitted for a 
reason other than that infection. An infection occurring in a patient in a hospital 
or other health care facility in whom the infection was not present or incubating at 
the time of admission. This includes infections acquired in the hospital but 
appearing after discharge, and also occupational infections among staff of the 
facility. 
Nosocomial infections are one of the occupational biohazards that affect 
the health of individuals with or without predisposing factors. These are the 
infections acquired during hospital stay, which are found in 5 to15% (two million 
cases are estimated annually) of hospitalized patients and can lead to complication 
in 25to 33% of those admitted in ICU. 
The increasing incidence of hospital acquired infections caused by 
antibiotic resistant pathogens has led to an increase in morbidity and mortality. 
Studies conducted in hospitals in Delhi and Mumbai report figures as high as 30%. 
Even in most advanced countries like US, as per Centre for Disease Control 
estimate hospital admission due to infections acquired from hospital stays is about 
4.5%. Resistance results from the interplay of microorganisms, patients and the 
hospital environment including antibiotic use and infection control practices. 
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According to the data published by the US Centers for Disease Control and 
Prevention (CDC) as part of their national nosocomial infection surveillance 
(NNIS) System, well over half of all intensive care unit isolates from documented 
infections are caused by methicillin-resistant S. aureus. The type, as well as 
severity, of S. aureus infections and its response to antibiotic treatment are dictated 
by the specific suite of virulence and antibiotic resistance associated genes carried 
by the strain of the S. aureus causing the infection. 
NOSOCOMIAL INFECTION SITES: 
 
ROLE OF HOSPITAL PHARMACIST IN INFECTION CONTROL: 
The hospital pharmacist is responsible for: 
 Obtaining, storing and distributing pharmaceutical preparations using 
practices which limit potential transmission of infectious agents to patients 
 Dispensing anti-infectious drugs and maintaining relevant records (potency, 
incompatibility, conditions of storage and deterioration) 
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 Obtaining and storing vaccines or sera, and making them available as 
appropriate 
 Maintaining records of antibiotics distributed to the medical departments 
 Providing the Antimicrobial Use Committee and Infection Control 
Committee with summary reports and trends of antimicrobial use 
 Having available the following information on disinfectants, antiseptics and 
other anti-infectious agents: 
o Active properties in relation to concentration, temperature, length of 
action, antibiotic spectrum 
o Toxic properties including sensitization or irritation of the skin and 
mucosa 
o Substances that are incompatible with antibiotics or reduce their 
potency 
o Physical conditions which unfavourably affect potency during 
storage: temperature, light, humidity 
o Harmful effects on materials. 
The hospital pharmacist may also participate in the hospital sterilization and 
disinfection practices through: 
 Participation in development of guidelines for antiseptics, disinfectants, and 
products used for washing and disinfecting the hands 
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 Participation in guideline development for reuse of equipment and patient 
materials 
 Participation in quality control of techniques used to sterilize equipment in 
the hospital including selection of sterilization equipment (type of 
appliances) and monitoring.
7
 
SURVEILLANCE: 
The systematic, ongoing collection, collation, analysis, interpretation and 
dissemination of data for public health action. 
 
AMR SURVELLIANCE: 
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AMR SURVEILLANCE NEEDED TO:  
 Detect resistant strains of public health importance  
 Support prompt notification and investigation of outbreaks  
 Inform clinical treatment decisions  
 Guide policy recommendations  
 Monitor efficacy of interventions and infection control measures 
NEED FOR THE STUDY: 
• Hospital-acquired infections result in significant morbidity and mortality, 
and contribute to escalating health care costs.  
• The emergence of resistance to antimicrobial agents, despite the availability 
of newer antibiotics, has become an increasing problem throughout the 
world, particularly in pathogens causing nosocomial infections.  
• For practicing physicians, clinical microbiologists and public health 
officials, knowledge of local antimicrobial resistance patterns is essential 
for the development of empirical and pathogen-specific therapy. The 
distribution of pathogens causing nosocomial infections changes with time 
and varies among hospitals. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature  
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REVIEW OF LITERATURE: 
M. Merchant et al., done a prospective study about the incidence of hospital-
acquired pneumonia in consecutive admissions to an 1800 bed hospital in Bombay; 
991 of them to general medical wards and 895 to a 17bed medical intensive care unit 
(ICU). The average bed occupancy in general ward was two nurses for 56 patients, 
and in the ICU three nurses for 17 beds. They found One hundred and sixty eight 
patients developed nosocomial pneumonia: 18 (1.8%) in general wards and 150 
(16.7%) in the ICU. Common isolates included Pseudomonas spp (44”/0) and 
Klebsiella spp (34%). The most frequently used antibiotics were cefotaxime (34%), 
amikacin (25%), gentamicin (23%) and ofloxacin (13%). Crude mortality in general 
ward patients was 88.9 vs 14.6% in patients without pneumonia. The corresponding 
figures for ICU patients were 67.4 vs 37.1%; 40% of the crude mortality in ICU 
patients with pneumonia was attributable to the infection. Infected patients stayed an 
additional 5.8 days in the ICU and 6.7 days in the general ward. Costs of additional 
stay and antibiotics accounted for 18.6% of the ICU budget. They concluded that the 
incidence of nosocomial pneumonia was lower than expected, despite occupancy 
exceeding bed capacity, low nurse:patient ratios, and extensive reuse of disposable 
respiratory therapy equipment. Nevertheless, nosocomial pneumonia imposes a 
significant financial burden on the already scarce resources available for intensive care 
in developing countries like India.
8 
H. Markogiannakis et al., evaluated the clinical and microbiological 
characteristics of the patients who developed an infection in surgical intensive care 
unit (SICU) of a university hospital in Greece. They done a prospective study of all 
patients who sustained an ICU-acquired infection from 2002 to 2004. Among 683 
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consecutive SICU patients, 123 (18.0%) developed 241 infections (48.3 infections per 
1000 patient-days). The mean age of patients was 66.7 _ 3.8 years, the mean 
APACHE II score (acute physiology and chronic health evaluation) on SICU 
admission was 18.2 _ 2.4, and the mean SOFA score (sepsis-related organ failure 
assessment) at the onset of infection was 8.8 _ 2. Of the study patients, 51.2% were 
women. Infections were: bloodstream (36.1%), ventilator-associated pneumonia 
(VAP; 25.3%, 20.3/1000 ventilator-days), surgical site (18.7%), central venous 
catheter (10.4%, 7.1/1000 central venous catheter-days), and urinary tract infection 
(9.5%, 4.6/1000 urinary catheter-days). The most frequent microorganisms found 
were: Acinetobacter baumannii (20.3%), Pseudomonas aeruginosa (15.7%), Candida 
albicans (13.2%), Enterococcus faecalis (10.4%), Klebsiella pneumoniae (9.2%), 
Enterococcus faecium (7.9%), and Staphylococcus aureus (6.7%). High resistance to 
the majority of antibiotics was identified. The complication and mortality rates were 
58.5% and 39.0%, respectively. Multivariate analysis identified APACHE II score on 
admission (odds ratio (OR) 4.63, 95% confidence interval (CI) 2.69—5.26, p = 0.01), 
peritonitis (OR 1.85, 95% CI 1.03—3.25, p = 0.03), acute pancreatitis (OR 2.27, 95% 
CI 1.05—3.75, p = 0.02), previous aminoglycoside use (OR 2.84, 95% CI 1.06—5.14, 
p = 0.03), and mechanical ventilation (OR 3.26, 95% CI: 2.43—6.15, p = 0.01) as risk 
factors for infection development. Age (OR 1.16, 95% CI 1.01—1.33, p = 0.03), 
APACHE II score on admission (OR 2.53, 95% CI 1.77—3.41, p = 0.02), SOFA score 
at the onset of infection (OR 2.88, 95% CI 1.85— 4.02, p = 0.02), and VAP (OR 1.32, 
95% CI 1.04—1.85, p = 0.03) were associated with mortality. They concluded that the 
Infections are an important problem in SICUs due to high incidence, multi-drug 
resistance, complications, and mortality rate.
9 
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R. Gadepalli et al., analysed risk factors for nosocomial meticillin-resistant 
Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs) in three Indian 
hospitals. They also determined antimicrobial resistance patterns and genotypic 
characteristics of MRSA isolates using pulsed-field gel electrophoresis (PFGE), 
multilocus sequence typing (MLST) and staphylococcal cassette chromosome 
(SCCmec) typing. Medical records of 709 patients admitted to three tertiary hospitals 
with nosocomial S. aureus SSTIs were clinically evaluated. Antimicrobial 
susceptibility testing of patient isolates was performed in accordance with Clinical and 
Laboratory Standards Institute guidelines, with meticillin and mupirocin resistance 
confirmed by multiplex polymerase chain reaction. PFGE analysis of 220 MRSA 
isolates was performed, followed by MLST and SCCmec typing of a selected number 
of isolates. MRSA was associated with 41%, 31% and 7.5% of infections at the three 
hospitals, respectively. Multiple logistic regression analysis identified longer duration 
of hospitalisation [odds ratio (OR): 1.78; OR: 2.83 for _20 days], intra-hospital 
transfer (OR: 1.91), non-infectious skin conditions (3.64), osteomyelitis (2.9), 
neurological disorders (2.22), aminoglycoside therapy (1.74) and clindamycin therapy 
(4.73) as independent predictors for MRSA SSTIs. MRSA isolates from all three 
hospitals were multidrug resistant, with fifteen clones (IeXV) recognised. A majority 
of the strains possessed type III cassette. The common sequence type (ST) 239 was 
considered the signature MLST sequence for PFGE clone III. This major MRSA clone 
III was closely related to the UK EMRSA-1 and was significantly more resistant to 
antibiotics. Dissemination of multidrug-resistant MRSA clones warrants continuous 
tracking of resistant genotypes in the Indian subcontinent.
10 
Talaat et al., measured the incidence rate of catheter-associated urinary tract 
infections (CAUTIs), identified risk factors associated with acquiring the infections; 
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and identified the etiologic and antibiotic resistant patterns associated with CAUTIs in 
the intensive care units (ICUs) of a large University Hospital in Alexandria, Egypt. 
They done a prospective active surveillance of CAUTIs in 4 ICUs during a 13-month 
period from January 1, 2007 through January 31, 2008 in Alexandria University 
Hospital using the standard Centers for Disease Control National Nosocomial 
Infection Surveillance (NNIS) case definitions. Rates were expressed as the number of 
infections per 1000 catheter days. 757 patients were monitored after ICU admission, 
with either existing indwelling urinary catheters (239), or got catheters inserted after 
ICU admission (518), for a total duration of 16301 patient days, and 10260 patient 
catheter days. A total of 161 episodes of infection were diagnosed, for an overall rate 
of 15.7 CAUTIs per 1000 catheter days. Important risk factors associated with 
acquiring CAUTI were female gender (Relative risk (RR), 1.7; 95% confidence 
interval (CI); 1.7-4.3), and previous catheterization within the same hospital admission 
(RR, 1.6; 95% CI; 1.3-1.96). Patients admitted to the chest unit, patients =40 years, 
patients with prolonged duration of catheterization, prolonged hospital and ICU stay 
had a significantly higher risk of acquiring CAUTIs. Out of 195 patients who had their 
urine cultured, 188 pathogens were identified for 161 infected patients; 96 (51%) were 
Candida, 63 (33.5%) gram negatives, 29 (15.4%) gram positives. The prevalence of 
ESBL producers among K. pneumonia and E. coli isolates was 56% (14/25) and 
78.6% (11/14), respectively. They concluded that the infection control policies and 
procedures, CAUTI rates remain a significant problem in Alexandria University 
hospital. Using the identified risk factors, tailored intervention strategies are now 
being implemented to reduce the rates of CAUTIs in these 4 ICUs.
11 
R. Agarwal et al., done a prospective, observational clinical study to 
determine the epidemiology, risk factors and outcome of infections in a Respiratory 
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Intensive Care Unit (RICU) of a tertiary care institute in northern India. They included 
201 patients (1285 patient days) admitted to RICU over a period of one-and-a-half 
years. A total of 77 infections were identified in 67 patients (33.5%). The infections 
included pneumonia (23%), sepsis of unknown origin (10.5%), bacteremia (7.5%), 
urinary tract infections (1.5%), catheter related blood stream infections (1%) and 
Clostridium difficile colitis (1%). The most commonly identified organisms were the 
Acinetobacter species (34.8%), Pseudomonas aeruginosa (23.9%) and Escherichia coli 
(15.2%). The median length of stay in patients with and without infection was 13 days 
(interquartile range, IQR, 28) and 4 days (interquartile range, IQR, 3), respectively (p 
< 0.0001). Multivariate analysis showed the following risk factors for ICU acquired 
infection: the admitting diagnosis of infection (odds ratio [OR] 3.3; 95% confidence 
intervals [CI] 1.06e10.1), length of stay in the RICU (OR, 1.2; 95% confidence 
intervals [CI] 1.1e1.33); renal failure (OR, 4.7; 95% CI, 1.52e14.41) and institution of 
parenteral nutrition (OR, 16.9; 95% CI, 1.07e 269.03). Multivariate analysis showed 
the following risk factors for death in ICU: APACHE II scores (OR, 1.06; 95% CI, 
1.01e1.11), and endotracheal intubation (OR, 5.07; 95% CI, 1.24e20.65). APACHE II 
scores (OR, 1.06; 95% CI, 1.01e1.11), and endotracheal intubation (OR, 5.07; 95% 
CI, 1.24e20.65). This study clearly documents a high prevalence rate of infections in 
the ICU, and the data suggest that occurrence of infections was associated with a 
prolonged ICU stay but had no significant effect on the final outcome.
12 
N. Taneja et al., done a prospective study in a burn unit of a tertiary care 
referral centre in North India. Patients with 20–70% TBSAB were enrolled. Seventy-
one patients developed 59 hospital-acquired infections (HAI); the infection density 
being 36.2 infections per 1000 patient days. Invasive wound infections were the 
commonest (33), followed by blood stream infections (22), urinary tract infections (3) 
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and pneumonia (1). Infection contributed to 75% of observed mortality. On logistic 
regression analysis, infected patients were more likely to die as well as stay longer in 
the hospital as compared to non-infected patients. Infected patients also had more 
central venous lines inserted. The mortality was related to percent TBSAB. Thirteen 
out of 18 patients who had TBSAB more than 60% died as compared to 5 out of 31 
with TBSAB less than 40%. Staphylococcus aureus, Pseudomonas aeruginosa and 
hemolytic streptococci (BHS) were the most frequent organisms causing hospital 
acquired infection. Except for BHS all other organisms were highly drug resistant. 
Better compliance with hand washing and barrier nursing techniques, stricter control 
over disinfection and sterilization practices and usage of broad spectrum antibiotics, 
and reduction of the environmental contamination with S. aureus are required to 
reduce the HAI rates.
13
  
S. Reunes et al., done a single-center retrospective (1992–2007), pairwise-
matched (1:1-ratio) cohort study To determine risk factors for nosocomial 
bloodstream infection (BSI) and associated mortality in geriatric patients in geriatric 
and internal medicine wards at a university hospital. In this study geriatric patients 
with nosocomial BSI were matched with controls without BSI on year of admission 
and length of hospitalization before onset of BSI. Demographic, microbiological, and 
clinical data are collected. In this study One-hundred forty-two BSI occurred in 129 
patients. Predominant microorganisms were Escherichia coli (23.2%), coagulase 
negative Staphylococci (19.4%), Pseudomonas aeruginosa (8.4%), Staphylococcus 
aureus (7.1%), Klebsiella pneumoniae (5.8%) and Candida spp. (5.8%). Matching was 
successful for 109 cases. Compared to matched control subjects, cases were more 
frequently female, suffered more frequently from arthrosis, angina pectoris and 
pressure ulcers, had worse Activities of Daily Living-scores, had more often an 
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intravenous or bladder catheter, and were more often bedridden. Logistic regression 
demonstrated presence of an intravenous catheter (odds ratio [OR] 7.5, 95% 
confidence interval [CI] 2.5–22.9) and being bedridden (OR 2.9, 95% CI 1.6–5.3) as 
independent risk factors for BSI. In univariate analysis nosocomial BSI was associated 
with increased mortality (22.0% vs. 11.0%; P=0.029). After adjustment for 
confounding covariates, however, nosocomial BSI was not associated with mortality 
(hazard ratio 1.3, 95% CI 0.6–2.6). Being bedridden and increasing age were 
independent risk factors for death. They concluded that the Intravenous catheters and 
being bedridden are the main risk factors for nosocomial BSI. Although associated 
with higher mortality, this infectious complication seems not to be an independent risk 
factor for death in geriatric patients.
14 
Couto et al., reported on nosocomial infections (NIs), causative organisms, 
and antimicrobial susceptibility patterns in neonates who were admitted to neonatal 
intensive care units (NICUs), and assess the performance of birth weight (BW) as a 
variable for riskstratified NI rate reporting. They done a prospective, 10-year follow-
up, open cohort study that involved six Brazilian NICUs was conducted. The NI 
incidence rates were calculated using different denominators. In this study Six 
thousand two hundred forty-three newborns and 450 NICU-months of data were 
analysed. This included 3603 NIs that occurred in 2286 newborns over 121,008 
patient-days. The most frequent NIs were primary bloodstream infection (pBSI; 
45.9%), conjunctivitis (12.1%), skin infections (9.6%), and pneumonia (6.8%). Only 
the pBSI (but not pneumonia or central venous catheter–related pBSI) rate distribution 
differed significantly with varying BW. Gram-negative rods (mainly Klebsiella sp. 
And Escherichia coli) were responsible for 51.6% episodes of pBSI. Gram-positive 
organisms (mainly coagulase-positive staphylococci) accounted for 37.4%. Candida 
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sp. was the fourth isolated organism. A high resistance to third-generation 
cephalosporins was recorded in K pneumoniae and E coli isolates. They concluded 
that the burden of NI, and identifies the major focus for future NI control and 
prevention programs. Except for pBSI, BW had a poor performance as a variable for 
risk-stratified NI rate reporting.
15
  
Jung et al., conducted a retrospective, observational study of 527 patients with 
HCAP or CAP who were hospitalized at Severance Hospital in South Korea between 
January and December 2008 to determine the differences between HCAP and CAP in 
terms of clinical features, pathogens, and outcomes, and to clarify approaches for 
initial antibiotic management. Of these patients, 231 (43.8%) had HCAP, and 296 
(56.2%) had CAP. Potentially drug-resistant (PDR) bacteria were more frequently 
isolated in HCAP than CAP (12.6% vs. 4.7%; P = 0.001), especially in the low-risk 
group of the PSI classes (41.2% vs. 13.9%; P = 0.027). In-hospital mortality was 
higher for HCAP than CAP patients (28.1% vs. 10.8%, P < 0.001), especially in the 
low-risk group of PSI classes (16.4% vs. 3.1%; P = 0.001). Moreover, tube feeding 
and prior hospitalization with antibiotic treatment within 90 days of pneumonia onset 
were significant risk factors for PDR pathogens, with odds ratios of 14.94 (95% CI 
4.62-48.31; P < 0.001) and 2.68 (95% CI 1.32-5.46; P = 0.007), respectively. They 
concluded that the HCAP patients with different backgrounds, various pathogens and 
antibiotic resistance of should be considered, and careful selection of patients 
requiring broad-spectrum antibiotics is important when physicians start initial 
antibiotic treatments.
16 
Oteo et al.,
 
reported the antibiotic susceptibility results of invasive 
Staphylococcus aureus in Spain by using European Antimicrobial Resistance 
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Surveillance System (EARSS) during the period of 2000-2002. The increasing 
prevalence of antibiotic resistance was a cause of serious concern, requiring an 
international approach to its management. In Europe, antimicrobial resistance of 
invasive pathogens has been monitored since 1998 by the European Antimicrobial 
Resistance Surveillance System (EARSS). The purpose of EARSS is to document 
variations in antimicrobial resistance over time and space to provide the basis for, and 
assess the effectiveness of, prevention programmes and policy decisions. They 
concluded that antibiotic multiresistance S. aureus was frequent in invasive S. aureus 
in Spain, with phenotypes changing over time. However, resistance was not uniform 
and varied according to several parameters, such as hospital size, patient age and 
hospital department. Therefore, properly designed and conducted surveillance systems 
will continue to be essential in providing safe and effective empirical therapies. 
Moreover, results obtained from these surveillance systems must be used to 
implement prevention programmes and policy decisions to prevent emergence and 
spread of antimicrobial resistance.
17 
Rahbar et al.,
 
 discussed the rate of nosocomial infection and the organisms 
involved as well as the antibiotic resistance in patients with bacteraemia. This study 
was helpful to track nosocomial bloodstream infections and emerging trends in 
antibiotic resistance. Study also reviewed that gram-positive cocci, including 
coagulase-negative staphylococci, Staphylococcus aureus, Streptococcus pneumonia 
were the most common causes of nosocomial bacteraemia and accounted for 42.3% of 
isolates. Gram-negative bacilli were responsible for another 42.3% of isolates; 
Pseudomonas aeruginosa was the predominant isolate. Patterns of drug resistance 
varied according to species of bacteria but were generally quite high.
18 
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Mizuta et al.,  evaluated the utility of a novel combination antibiogram to 
determine the optimal combination of antimicrobial agents for empirical therapy of 
Pseudomonas aeruginosa infection. Infections due to antibiotic-resistant bacteria are 
associated with increased morbidity and mortality. Administration of inadequate 
empirical antibiotic therapy has been frequently associated with increased mortality. A 
common cause of inadequate therapy is infection with an antibiotic-resistant pathogen.  
One potential option is to use empirical dual antimicrobial therapy, with the hope that 
at least one of the selected agents will be active against the infecting pathogen. Dual 
therapy is commonly used when infection due to Pseudomonas aeruginosa is 
suspected. In the current best-case scenario, one would consult the local antibiogram 
to determine the two agents to which P. aeruginosa is most often susceptible. They 
also suggested that the combination antibiogram allowed modest fine-tuning of 
choices for dual antibiotic therapy, selections based on the two antibiograms did not 
differ substantively. Drug combinations with the broadest coverage were consistently 
composed of an amino glycoside and a ß-lactam.
19 
Vatopoulos et al.,  described that an electronic network for the surveillance of 
antimicrobial resistance in bacterial nosocomial isolates in Greece during the period of 
January-December 1996. The results illustrated the positive impact of a national or 
international surveillance network in preventing and confronting antimicrobial-
resistant bacterial diseases. Again this study demonstrated the potential of the 
electronic network for studying the patterns and trends in the epidemiology of 
antimicrobial resistance in the various participating hospitals. This would contribute to 
identification of the main factors for the emergence of resistance, as well as the 
priorities for further investigating the genetic and molecular mechanisms responsible, 
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and thus for the development of a strategy to confront this major public health 
problem.
20 
 Smith et al., investigated the patients with infections due to Staphylococcus 
aureus, with intermediate glycopeptides resistance. Staphylococcus aureus was one of 
the most common causes of nosocomial and community- acquired infection. Since the 
emergence of Methicillin-resistant S. aureus, the glycopeptide Vancomycin has been 
the only uniformly effective treatment for staphylococcal infections. After performing 
the study, they concluded that the emergence of  S. aureus with intermediate 
glycopeptide resistance threatens to return us to the era before the development of 
antibiotics. To prevent further emergence of  S. aureus strains with intermediate 
glycopeptide resistance and the emergence of S. aureus with full Vancomycin 
resistance, the use of Vancomycin must be optimized, laboratory methods for the 
detection of resistant pathogens must be enhanced, and infection-control precautions 
must be strictly followed for infected or colonized patients.
21 
Karlowsky et al.,
 
evaluated the continued effectiveness of available 
antipseudomonal antimicrobial agents in United States. The potential for antimicrobial 
resistance was an important concern for clinicians treating patients with confirmed or 
suspected P. aeruginosa infections. Empirical therapy for a patient with a serious 
infection for which the suspected etiologic agent is P. aeruginosa generally consists of 
an antipseudomonal β-lactam (e.g., Carbapenem, Ceftazidime, Cefepime, Piperacillin, 
or Piperacillin-Tazobactum) as monotherapy or the combination of an 
antipseudomonal ß-lactam with an Aminoglycoside or a Fluoroquinolone (e.g., 
Ciprofloxacin or Levofloxacin). Their result showed that the susceptibility of clinical 
isolates of P. aeruginosa to Piperacillin-Tazobactam, Ceftazidime, and 
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Fluoroquinolones (Ciprofloxacin and Levofloxacin) remained stable. Isolates of P. 
aeruginosa with multidrug resistance phenotypes were slowly becoming increasingly 
prevalent at the expense of a decrease in the prevalence of isolates with single-drug 
resistance phenotypes. New antimicrobial agents with activity against P. aeruginosa 
will not be available in the near future, ongoing surveillance of the activities of 
currently available agents were critical.
22 
Klevens et al., presented the incidence rates and estimated number of invasive 
MRSA infections and in-hospital deaths among patients with MRSA in the United 
States in 2005. The standardized incidence rate of invasive MRSA was 31.8%. 
Incidence rates were highest among persons 65 years and older, blacks and males. 
There were 1598 in-hospital deaths among patients with MRSA infection during the 
surveillance period. In 2005, the standardized mortality rate was 6.3%. They also 
concluded that invasive MRSA infection affects certain populations 
disproportionately. It was a major public health problem primarily related to health 
care but no longer confined to intensive care units, acute care hospitals, or any health 
care institution.
23 
Troillet et al.,
 
evaluated potential risk factor  for the detection of Imipenem-
resistant Pseudomonas aeruginosa in clinical specimens from hospitalized patients. 
Imipenem, a broad-spectrum ß-lactam antibiotic and the first Carbapenem approved 
for clinical use, in an important drug for treatment of Pseudomonas aeruginosa 
infections. It offers the advantage of being more stable to most ß-lactamases secreted 
by P. aeruginosa than any other antipseudomonal ß-lactam drugs, including the third-
generation Cephalosporins. They concluded that, treatment with Imipenem was the 
major risk factor for the clinical detection of Imipenem-resistant P. aeruginosa in 
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hospitalized patients. No other risk factor related to the hospital environment was 
identified. The use of other ß-lactam antibiotics, including third-generation 
Cephalosporins, did not predict resistance to Imipenem, even though Imipenem-
resistant P. aeruginosa isolates were more likely to be  resistant to other common 
antipseudomonal drugs than were  Imipenem-susceptible isolates.
24 
Obritsch et al.,
 
demonstrated the significant increases in resistance to single 
antipseudomonal agents, multidrug resistance, and dual resistance to commonly 
prescribed combination therapies among P. aeruginosa isolates during the 10-year 
period from 1993 to 2002 by using the intensive care unit surveillance study database. 
Nosocomial infections caused by Pseudomonas aeruginosa in critically ill patients 
were often difficult to treat due to resistance to multiple antimicrobials. The selection 
of appropriate antimicrobial therapy requires active surveillance of emerging 
resistance trends and continuing education among the health care providers and 
institution involved. They also suggested that susceptibility of antipseudomonal agents 
against ICU isolates decreased while multidrug resistance and dual resistance rates 
increased from 1993 to 2002. Significant reduction in susceptibilities of P. aeruginosa 
isolates may compromise the ability to choose efficacious empirical regimens for 
treatment of this formidable pathogen in critically ill patients. This study also provided 
valuable information related to emerging trends in resistance, and dual resistance rates 
which were vital to clinicians in the selection of reliable empirical therapy for P. 
aeruginosa infections in ICU.
25 
Aubert et al.,  analyzed the effect of reducing prescription of fluoroquinolones 
in an intensive care unit (ICU) upon bacterial resistance, particularly as regards 
Pseudomonas aeruginosa., administration of fluoroquinolones was kept to a 
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minimum. There was a 75.8% restriction in prescriptions of fluoroquinolones. There 
was no significant change in bacterial ecology between the periods preceding (12 
months) and following (12 months) restriction. There was a significant recovery of 
sensitivity of P. aeruginosa to ciprofloxacin with a decrease in resistant strains from 
71.3% in the prerestriction period to 52.4% in the post-restriction period. Regarding 
clinical data, no significant differences were noted between the pre-restriction and the 
post-restriction  periods, except for the number of cases of ventilator associated 
pneumonia with  P.  aeruginosa resistant to ciprofloxacin. This study also 
demonstrated the possibility of introducing rotation of antibiotics in an ICU.
26 
Hanberger et al., evaluated the incidence of decreased antibiotic susceptibility 
among aerobic gram-negative bacilli isolated from patients in ICUs in 5 European 
countries (Belgium, France, Portugal, Spain, and Sweden) by using determination of 
minimum inhibitory concentration. More than 20% of patients admitted to European 
intensive care unit (ICUs) develop an ICU acquired infection. The results showed that 
the most frequently isolated organisms were Enterobacteriaceae, followed by 
Pseudomonas aeruginosa. The main sources were respiratory tract, urine, blood, 
abdomen, and skin and soft tissue. Decreased antibiotic susceptibility across all 
species and drugs was highest in Portuguese ICUs followed by French, Spanish, 
Belgian, and Swedish ICUs. The highest incidence of resistance was seen in all 
countries among P. aeruginosa (up to 37% resistant to Ciprofloxacin in Portuguese 
ICUs and 46% resistant to Gentamicin in French ICUs), Enterobacter species, 
Acinetobacter species, and Stenotrophomonas maltophilia, and in Portugal and France 
among Klebsiella species. The high incidence of reduced antibiotic susceptibility 
among gram-negative bacteria in these ICUs suggested that more effective strategies 
were needed to control the selection and spread of resistant organisms. So they 
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suggested that hospitals should have an active program for online antibiotic resistance 
surveillance of common drugs, using quantitatively accurate minimum inhibitory 
concentration methods, to constantly evaluate antibiotic administration and pharmacy 
formulary options.
27 
Bantar et al., presented that laboratory-based data underestimate the 
frequency of several major resistant organisms in patients with hospital-acquired 
infection. Increasing bacterial resistance was a worrisome problem, especially in the 
nosocomial setting. Variation in the frequency of these resistant bacteria was 
monitored by several surveillance systems worldwide. These systems make use of a 
network of laboratory-generated antibiograms that were constructed on the basis of the 
cumulative antimicrobial susceptibility data from each hospital. Antibiograms were 
currently used to estimate the impact of changes in antibiotic usage and to determine 
infection control strategies and antibiotic usage policies. Furthermore, within the 
nosocomial setting, antibiograms were often taken into account to define a rational 
selection of the empirical antimicrobial therapy for treating patients with hospital-
acquired infections. Clinical validation of the individual susceptibility reports, 
performed by a multidisciplinary team prior to data entering, seems to be a suitable 
strategy to get more reliable data to guide the rational selection of antimicrobial 
empirical therapy in patients with hospital-acquired infections.
28 
Carmeli et al.,  analysed relative risks for emergence of resistant 
Pseudomonas aeruginosa in patients, associated with four antipseudomonal agents 
like Ciprofloxacin, Ceftazidime, Imipenem, and Piperacillin. Pseudomonas 
aeruginosa was a leading cause of nosocomial infections. The risk of emergence of 
antibiotic resistance may vary with different antibiotic treatments. P.aeruginosa 
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showed a particular propensity for the development of resistance. The emergence of 
resistance in P.aeruginosa also limits future therapeutic choices and is associated with 
increased rates of mortality and morbidity and higher costs. Knowledge about the 
relative risks of emergence of resistance with different antibiotics could be useful in 
helping to guide therapeutic choices. Result showed that out of 271 patients, resistance 
emerged in 28 patients. There were evident differences among antibiotics in the 
likelihood that their use would allow emergence of resistance in P.aeruginosa. 
Ceftazidime was associated with the lowest risk, and Imipenem had the highest risk.
29 
Lautenbach et al., illustrated risk factors for infection with Imipenem-
resistant Pseudomonas aeruginosa and also determined the impact of Imipenem 
resistance on clinical and economic outcomes among patients infected with P. 
aeruginosa. Imipenem remains among the most reliable agents for treating P. 
aeruginosa infection, decisions regarding antibiotic therapy have become increasingly 
complicated in recent years because of the emergence of significant antibiotic 
resistance in these pathogens. They concluded that the prevalence of Imipenem 
resistance among P. aeruginosa isolates has increased significantly over the past 10 
years and that Fluoroquinolone use was strongly associated with Imipenem-resistant P. 
aeruginosa infection. Infection with Imipenem-resistant P. aeruginosa was 
significantly associated with increased mortality rate, duration of hospitalization, and 
hospital costs. They demonstrated the urgency of addressing the continued emergence 
of Imipenem-resistant P. aeruginosa strains and further suggested that increased use of 
other antibiotics (ie, Fluoroquinolones) may be important in explaining current trends 
of resistance to Carbapenems.
30 
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 Melinda et al., assessed national rates of antimicrobial resistance among gram 
negative aerobic isolates recovered from ICU patients and compare these rates to 
antimicrobial use. Susceptibility data derived from national surveillance can be a 
barometer of emerging resistance problems. The results showed that high incidence of 
reduced antibiotic susceptibility among gram-negative bacteria. They also documented 
the increasing incidence of Ciprofloxacin resistance among gram-negative bacilli that 
has occurred coincident with increased use of fluoroquinolones. Fluoroquinolones that 
are not affected by currently circulating resistance mechanisms need to be developed 
to conserve this class of agents. In the meantime, ongoing surveillance and more 
judicious use of Fluoroquinolone antibiotics will be necessary to limit this downward 
trend in susceptibility.
31 
 Gasink et al.,  evaluated risk factors for infection or colonization with 
Aztreonam-resistant Pseudomonas aeruginosa and examined the impact of this 
organism on mortality. They concluded that Aztreonam resistance in P. aeruginosa 
was an important problem that has been largely ignored. Infection with an Aztreonam-
resistant strain of P. aeruginosa did not appear to have a significant impact on 
mortality, the loss of effective therapeutic agents to treat P. aeruginosa was of great 
concern, and increases in the prevalence of Aztreonam-resistant P. aeruginosa further 
limit the available antipseudomonal armamentarium. Efforts should be made to 
preserve the utility of Aztreonam by curbing unwarranted use of Fluoroquinolones and 
agents active against anaerobes. Their study also provided additional evidence that 
restriction of Fluoroquinolone use was critically important in the fight against the 
emergence of antimicrobial resistance.
32 
Chamot et al., studied the rates of survival among patients who received 
either monotherapy or combination therapy for Pseudomonas aeruginosa bacteremia. 
27 
 
In this study they found the hazard of death from the date of receipt of the antibiogram 
to day thirty was higher for both inadequate empirical therapy and adequate empirical 
monotherapy than for adequate empirical combination therapy. Compared to adequate 
definitive combination therapy, the risk of death at thirty days was also higher with 
inadequate definitive therapy but not with adequate definitive monotherapy. They 
concluded that clinicians who expect Pseudomonas aeruginosa bacteremia initiate 
empirical therapy with two antipseudomonal agents. In the case of confirmed 
Pseudomonas aeruginosa bacteremia, this combination therapy could be altered to 
monotherapy on the basis of the specific susceptibility pattern of the initial isolate.
33 
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AIM AND OBJECTIVES 
AIM  
  The primary aim of the study is to evaluate the resistance patterns of 
microorganisms to various antibiotics in Nosocomial infections undertaking a 
surveillance study by using antibiogram reports. 
 
OBJECTIVES 
 To conduct a surveillance study on antibiotic resistance in patients 
with Nosocomial infections using antibiogram reports. 
 To determine the sensitivity patterns of microorganisms to the 
antibiotics prescribed during the study period. 
 To determine the resistance patterns of microorganisms to the 
antibiotics prescribed during the study period. 
 To monitor the extent of compliance of antibiotics prescribed with 
the results of antibiograms. 
 To understand the present prescribing patterns of antibiotics in 
nosocomial infections in the hospital. 
 To aid in optimum drug therapy by promoting rational use of 
antibiotics. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plan of Study 
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PLAN OF STUDY 
PHASES STEPS ACTIVITY TIME PERIOD 
PHASE I 
STEP I 
Identification of 
target areas for 
possible study 
July ’11 
STEP II Literature survey July’11 
STEP III 
Define criteria and 
standards 
Aug ’11 
STEP IV 
Designing of data 
entry form 
Aug ’11 
PHASE II STEP V 
Collection of 
patient’s lists with 
antibiogram report 
Sep ’11 - Jan ’12 
PHASE III STEP VI 
Collection of 
prospective data 
from patients 
Sep ’11 - Jan ’12 
PHASE IV STEP VII Analysis of Data Jan ‘12 
  
 
 
 
 
 
 
 
 
 
 
 
 
Methodology  
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METHODOLOGY 
The study was conducted in Kovai Medical Center and Hospital; a 
modernized 657 bedded multidisciplinary advanced super specialty hospital at 
Coimbatore. It is one of the largest hospitals in Coimbatore which excels in diverse 
specialized fields like Nephrology, Neurology, Cardiology, Pulmonology, 
Orthopedics, Oncology, Dermatology, Gynecology, Endocrinology, Pediatrics, 
General medicine, General surgery, ENT, Dentistry, Gastroenterology and 
Physical medicine and rehabilitation. 
Study Design: 
The study was designed to determine the susceptibility of isolates of 
microorganisms to antibiotics. The details of the bacterial strains isolated from any 
specimens of patients suffering from nosocomial infections were collected and 
studied. The study is a Prospective observational study. 
Study Site: 
The study was conducted at the Department of Microbiology in Kovai 
Medical Center and Hospital, a super specialty hospital in Coimbatore.  
Study Period: 
The study was conducted over a period of seven months from July 2011 to 
January 2012. 
Study Population: 
A total of 25 subjects were included in the study. 
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Study Criteria: 
Inclusion Criteria   
 Patients with positive cultures after 48 hours of hospitalization. 
 Patients for whom antibiotic sensitivity testing was performed.  
Exclusion Criteria 
 Out patients 
 Patients receiving antibiotics without obtaining antibiogram report. 
 Patients who present with positive culture at the time of 
hospitalization.  
Study Protocol: 
 Topic Selection 
Current levels of antibiotic resistance have reached critical levels with 
many epidemic clones of multiply resistant organisms such as Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella species causing 
increased morbidity and mortality, particularly amongst the elderly and immuno-
compromised. Urgent action is needed locally, nationally and internationally to 
contain this epidemic. Resistance surveillance is well established as an essential 
cornerstone of any attempts to understand and control resistance. Hence this study 
focuses on antibiotic surveillance program to assess the extent of the problem. 
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 Literature Review 
An extensive literature survey was done on, antimicrobial usage, 
antimicrobial resistance, challenges of antimicrobial resistance, strategies to 
minimize the spread of antimicrobial resistance, importance of antibiogram 
surveillance method etc. The literatures supporting the study were gathered from 
various journals like Clinical Infectious Diseases, British medical journal, Journal 
of antimicrobial chemotherapy etc. The articles from the journals were mainly 
collected with the help of SCIENCE DIRECT, IOWA DRUG INFORMATION 
SYSTEMS (IDIS), MEDLINE and from other Internet sources. Informations were 
also gathered from documents published by WHO. 
 
 Development of patient data entry form 
A well-designed data entry form was used for collecting data for this study. 
Data collected included patient details, antibiotics prescribed and other drugs 
prescribed. For every subject in this study patient name, inpatient number, date of 
admission, age, sex, ward of admission and length of stay in the hospital were 
recorded. Details of antibiotic therapy such as name of the antibiotics, dose, route 
of administration, frequency of administration and duration of therapy and 
antibiogram report were recorded. 
 
 Consent from Ethics Committee: 
The authorization for conducting this study in the hospital was obtained 
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from the Chairman and approved by Ethics committee Kovai Medical Center and 
Hospital, Coimbatore on 17
th
 September 2011.  
 Prospective Study 
In this phase of study the details of patients for whom antibiotic 
susceptibility testing was done for nosocomial infections were collected 
prospectively from the microbiology laboratory and patient files were obtained 
directly from the wards thereby obtaining antibiogram report and other patient’s 
details for a period of seven months from July 2011 to January 2012. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
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RESULTS AND DISCUSSION 
The study was carried out at Kovai Medical Center and Hospital over a 
period of seven months from July 2011 to January 2012. A prospective 
observational study in which data pertaining to the time period between July 2011 
to January 2012 were collected. 
During the entire study period, a total of 69 patients antibiogram report 
were collected. Of these, 25 patients were identified as Nosocomial infections. The 
data of 25 patients were collected as part of the prospective study. The results of 
the study are as follows: 
Evaluation of the demographic data of the subjects revealed that among the 
25 patients included in this study, 64% (n=16) were male while 36% (n=9) were 
female. Nosocomial infections was more common among men than among 
women.
34
 This gender disparity in Nosocomial infections could be also due to 
patients those who were admitted in ICUs, mainly from road-traffic accidents and 
men were more prone to this. [Tab 1, Fig 1] 
Age group analysis of the patients showed that, the most prominent age 
group were ‘61-70’ years and ’31-40’ years each comprising of 32% (n=8) and 
20% (n=5) respectively. Our data showed that majority of Nosocomial infection 
cases were among patients over 60 years old. This might be due to decrease in the 
immunity in this age group.
35
 [Tab 2, Fig 2] 
The study showed that the most important department generating the 
highest number of positive cultures were neurolosurgery department with 36% 
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(n=9) followed by Orthopedics 20% (n=5). Among these departments, most of the 
patients were admitted in ICUs only, and those who were critically ill or 
immunocompromised requiring mechanical support and indwelling devices.
35 
[Tab 
3, Fig3] 
Nosocomial infections contribute to extra hospital days and causing extra 
charges per hospitalization.
36
 Our study also showed that from a total of 25 cases, 
most of the patients 24% (n=6) were admitted for more than 30 days followed by 
16% (n=4) were 6-10 days. So these longer hospital stay could be a major reason 
for the emergence of organisms resistant to the antibiotic therapy. [Tab 4, Fig 4] 
The monitoring of the antibiotic therapy among the patients those who 
were admitted during the entire study period showed that most of the patients 
received one antibiotic as per their treatment schedule i.e 52% (n=13) followed by 
40% (n=10) patients were on more than one antibiotics. The usage of multiple 
antibiotics in the hospital settings could thus be a major reason for the increase in 
antibiotic resistance.  [Tab 5, Fig 5]  
The most commonly prescribed antibiotics during the entire study period 
were Amoxicillin/ Clavulanic acid which was accounted by 21.88% prescriptions, 
followed by Cefoperazone/ Sulbactam (15.63%), Colistinmethate sodium (15.63%) 
and Amikacin (12.5%) etc. [Tab 6, Fig 6] 
Out of the 25 cases identified, gram-negative organisms were highly 
prevalent of 96% (n=24) than gram-positive organisms of 4% (n=1). However 
many studies revealed that gram-positive organisms have over taken gram-
negative species in terms of prevalence.
35,38,39,34
  The culture reports also specified 
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the microorganisms isolated from each specimen. This data indicated the 
prevalence of Klebsiella species and Escherichia coli to be the highest over all 
other organisms during the entire study period. Isolates of Klebsiella species were 
found to be 72% (n=18) of all specimens while Escherichia coli  isolates were 
found to be 20% (n=5) specimens. Followed by Staphylococcus and Pseudomonas 
species accounted by 4% (n=1) each. [Tab 7, Fig 7] 
The antibiotic therapy given to each individual was reviewed against the 
corresponding antibiogram report and the following observations were made. Of 
the 25 cases, 24% (n=6) of subjects the antibiotics given empirically were found to 
be sensitive to the microorganism according to the antibiogram. In 48% (n=12) of 
the patients, the antibiotics given empirically were changed according to the 
antibiogram report. In 28% (n=7) of the patients, the antibiogram reports did not 
translate into any changes in the choice of antibiotics given. These inadequate 
administration of antimicrobial treatment may contribute antimicrobial resistance 
which would be an important determinant of patient outcome.
37 
[Tab 8, Fig 8] 
Antibiotic susceptibility testing was done on these isolates to determine the 
susceptibility of the isolate to an array of antibiotics which would determine the 
extent of resistance or sensitivity of the organism to each antibiotic. The following 
antibiotics were included the study for susceptibility testing according to the 
antibiogram reports.  
Colistinmethate sodium, Tigecycline, Amoxicillin/ Clavulanic acid, 
Piperacillin/ Tazobactum, Cefoperazone/ Sulbactum, Ceftriaxone, Cefotaxime, 
Cefepime, Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Amikacin, 
Doxycycline, Imipenem, Ertapenem, Meropenem, Vancomycin, Linezolid. 
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Of the 18 isolates of Klebsiella species, 100% (n=18) resistance were found 
in Amoxicillin/Clavulanic acid, Ceftriaxone, Cefotaxime, Cefepime, 
Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Doxycycline while 94.12% 
(n=16) in Cefoperazone/Sulbactum, 93.75% (n=15) in Piperacillin/Tazobactum, 
72.22% (n=13) in Amikacin, Ertapenem, Meropenem. Similarly 100% sensitivity 
were found in Colistinmethate sodium and Tigecycline followed by 33.33% (n=6) 
in Imipenem, followed by 27.78 (n=5) in Meropenem and Ertapenem each.[Tab 9, 
Fig 9: A-B]  
 A study by Anastasia et al. concluded that the existence and prolonged or 
inadequate use in the critically ill patients with multi drug resistant gram negative 
pathogens may lead to the emergence of colistimethate sodium resistance. The 
latter events urge for the development of new antimicrobials against multi resistant 
gram negative pathogens, the prudent use of colistimthate sodium and the strict 
implementation of hand hygene rules.
40 
All the 5 isolates of Escherichia coli, 100% (n=5) resistant to 
Amoxicillin/Clavulanic acid, Ceftriaxone, Cefotaxime, Ciprofloxacin, Ofloxacin, 
Levofloxacin, Moxifloxacin, Doxycycline, Vancomycin, Linezolid while 80% 
(n=4) resistant to Piperaciline/Tazobactum, Cefoperazone, Cefepime, Amikacin, 
Ertapenem and Meropenem, 60% (n=3)  for Imipenem. At the same time 100% 
sensitivity were found in Colistinmethate sodium and Tigecycline followed by 
40% (n=2) in Imipenem. [Tab 9, Fig 9: C-D] 
The results of the study shows that the isolated E. coli exhibitted multiple 
resistance to a number of commonly used antimicrobials. Similar observations 
have also been recorded in another study by Adejuwon et al.
41 
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A total of 25 patients, 4% (n=1) were identified as the isolates of 
Staphylococcus aureus. Of these, 100% resistance was found in 
Amoxicillin/Clavulanic acid, Piperacillin/Tazobactum, Cefoperazone/Sulbactum, 
Ceftriaxone, Cefotaxime and Cefepime. Similarly 100% of sensitivity was also 
found in Tigecycline, Doxycycline, Vancomycin. These observed results of  
Vancomycin  also similar in the study carried out by Oteo et al.
17
 [Tab 9, Fig 9: E]  
A total of 25 patients, 4% (n=1) were identified as the isolates of 
Pseudomonas species. Among this 100% were found to be resistant to 
Amoxicillin/ Clavulanic acid, Piperacillin/Tazobactum, Cefoperazone, 
Ceftriaxone, Cefotaxime, Cefepime, Ciprofloxacine, Ofloxacin, Moxifloxacin and 
Doxycycline. At the same time 100% of sensitivity was also found in 
Colistinmethate sodium, Amikacin, Imipenem, Meropenem. The observed 
sensitivity to Imipenem is in contrast to the results given by Hanberger et al.
27 
[Tab 
9, Fig 9: F-G] 
                  
  
 
 
 
 
 
 
 
 
 
 
 
 
Tables & Graphs 
39 
 
TABLE: 1 
GENDER DISTRIBUTION 
Gender Number of Patients (n=25) 
Male 16 (64%) 
Female 9 (36%) 
 
 
FIGURE: 1 
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TABLE: 2 
AGE DISTRIBUTION 
Age in Years Number of Patients (n=25) 
<1 1 (4%) 
1-10 0 (0%) 
11-20 0 (0%) 
21-30 2 (8%) 
31-40 5 (20%) 
41-50 3 (12%) 
51-60 2 (8%) 
61-70 8 (32%) 
71-80 3 (12%) 
81-90 1 (4%) 
91-100 0 (0%) 
 
FIGURE: 2 
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TABLE: 3 
DISTRIBUTION OF PATIENTS WITH DEPARTMENTS 
Department Number of Patients  (n=25) 
Paediatrics 1 (4%) 
Neuro surgery 9 (36%) 
Orthopedics 5 (20%) 
General Surgery 3 (12%) 
Nephrology 2 (8%) 
Pulmonology 2 (8%) 
Others 3 (12%) 
 
 
 
Figure: 3 
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TABLE: 4 
DURATION OF STAY IN HOSPITAL 
Duration of Stay in Hospital Number of Patients (n=25) 
1-5 4 (16%) 
6-10 4 (16%) 
11-15 3 (12%) 
16-20 3 (12%) 
21-25 3 (12%) 
26-30 2 (8%) 
>31 6 (24%) 
 
 
 
FIGURE: 4 
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TABLE: 5 
NUMBER OF ANTIBIOTICS PRESCRIBED PER PATIENT 
Number of Antibiotics Number of Patients  (n=25) 
One 13 (52%) 
Two 6 (24%) 
Three 4 (16%) 
Greater than Three 2 (8%) 
 
 
 
 
FIGURE: 5 
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TABLE: 6 
COMMONLY USED ANTIBIOTICS 
Commonly Used Antibiotics Number of Patients (n=25) 
Amoxicillin/Clavulanic acid 7 (21.85%) 
Cefoperazone/Sulbactum 5 (15.63%) 
Amikacin 4 (12.5%) 
Linezolid 2 (6.25%) 
Moxifloxacin 2 (6.25%) 
Tigecycline 1 (3.13%) 
Colistimethate sodium 5 (15.63%) 
Cefepime/Tazobactum 2 (6.25%) 
Imipenem 2 (6.25%) 
Piperacillin/Tazobactum 2 (6.25%) 
 
 
FIGURE: 6 
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TABLE: 7 
DISTRIBUTION OF MICROORGANISM 
Microorganism Isolated Number of Patients (n=25) 
Escherichia coli 5 (20%) 
Klebsiella species 18 (72%) 
Staphylococcus aureus 1 (4%) 
Pseudomonas species 1 (4%) 
  
 
 
 
FIGURE: 7 
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TABLE: 8 
MODE OF TREATMENT BASED ON ANTIBIOGRAM REPORT 
Mode of Treatment Number of Patients (%) (n=25) 
Patients Empirically Started on 
Sensitive Antibiotics 
6 (24%) 
Antibiotics Changed According to 
Antibiogram 
12 (48%) 
Antibiotics Not Changed According 
to Antibiogram 
7 (28%) 
 
 
 
 
FIGURE: 8 
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TABLE: 9 
SENSITIVITY PATTERN OF INDIVIDUAL ANTIBIOTIC TO VARIOUS MICROORGANISMS 
Antibiotics 
Klebsiella species 
(n=18) 
Escherichia coli 
(n=5) 
Staphylococcus aureus 
(n=1) 
Pseudomonas species 
(n=1) 
S R S R S R S R 
Colistimethate 
sodium 
15 
(100%) 
- 
3 
(100%) 
- - - 
1 
(100%) 
- 
Tigecycline 
14 
(100%) 
- 
3 
(100%) 
- 
1 
(100%) 
- - - 
Amoxicillin/ 
Clavulanic acid 
- 
18 
(100) 
- 
5 
(100%) 
- 
1 
(100%) 
- 
1 
(100%) 
Piperacillin/ 
Tazobactum 
1 
(6.25%) 
15 
(93.75%) 
1 
(20%) 
4 
(80%) 
- 
1 
(100%) 
- 
1 
(100%) 
Cefoprazone/ 
Sulbactum 
1 
(5.88%) 
16 
(94.12) 
1 
(20%) 
4 
(80%) 
- 
1 
(100%) 
- 
1 
(100%) 
Ceftriaxone - 
18 
(100%) 
- 
5 
(100%) 
- 
1 
(100%) 
- 
1 
(100%) 
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Antibiotics 
Klebsiella species 
(n=18) 
Escherichia coli 
(n=5) 
Staphylococcus aureus 
(n=1) 
Pseudomonas species 
(n=1) 
S R S R S R S R 
Cefotaxime - 
18 
(100%) 
- 
5 
(100%) 
- 
1 
(100%) 
- 
1 
(100%) 
Cefepime - 
18 
(100%) 
1 
(20%) 
4 
(80%) 
- 
1 
(100%) 
- 
1 
(100%) 
Ciprofloxacin - 
18 
(100%) 
- 
5 
(100%) 
- - - 
1 
(100%) 
Ofloxacin - 
18 
(100%) 
- 
5 
(100%) 
- - - 
1 
(100%) 
Levofloxacin - 
18 
(100%) 
- 
5 
(100%) 
- - - - 
Moxifloxacin - 
18 
(100%) 
- 
5 
(100%) 
- - - 
1 
(100%) 
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Antibiotics 
Klebsiella species 
(n=18) 
Escherichia coli 
(n=5) 
Staphylococcus aureus 
(n=1) 
Pseudomonas species 
(n=1) 
S R S R S R S R 
Amikacin 
5 
(27.78%) 
13 
(72.22%) 
1 
(20%) 
4 
(80%) 
- - 
1 
(100%) 
- 
Doxycyclin - 
18 
(100%) 
- 
5 
(100%) 
1 
(100%) 
- - 
1 
(100%) 
Imipenem 
6 
(33.33%) 
12 
(66.67%) 
2 
(40%) 
3 
(60%) 
- - 
1 
(100%) 
- 
Ertapenem 
5 
(27.78%) 
13 
(72.22%) 
1 
(20%) 
4 
(80%) 
- - - - 
Meropenem 
5 
(27.78%) 
13 
(72.22%) 
1 
(20%) 
4 
(80%) 
- - 
1 
(100%) 
- 
Vancomycin - - - 
5 
(100%) 
1 
(100%) 
- - - 
Linezolid - - - 
5 
(100%) 
- - - - 
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FIGURE: 9-A 
 
FIGURE: 9-B 
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FIGURE: 9-C 
 
FIGURE: 9-D 
 
Antibiotics 
 
Antibiotics 
 
52 
 
FIGURE: 9-E 
 
FIGURE: 9-F 
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FIGURE: 9-G 
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SUMMARY AND CONCLUSION 
A total of 25 in-patients, included in the study between July 2011 to 
January 2012 and for whom antibiotic sensitivity testing was performed against 
various microorganisms isolated from their specimens mainly urine and blood, 
were reviewed during the entire study period. Nosocomial was more common 
among men than among women in this study. A high percentage of patients aged 
between ‘61-70’ in this study population showed that patients over 60 years old are 
more prone to nosocomial infections.   
The culture reports revealed that gram-negative organisms like Klebsiella 
species, eshcerichia coli, pseudomonas species were the predominant organisms 
causing HAI followed by staphylococcus aureus, a gram-positive organism. A 
total of 25 specimens containing 4 various microorganisms, underwent 
susceptibility testing against various antibiotics, among this 19 antimicrobials were 
included in this study. 
Combination of β-lactam antibiotics with β-lactamase inhibitors are now 
very commonly used in the treatment of various infections. It is usual for the 
physicians to use these combinations as empirical therapy. Among this group, 
Piperacillin/ Tazobactum and Cefoperazone/ Sulbactum were showed higher 
sensitivity than Amoxicillin/ Clavulanic acid against various microorganisms in 
this study. The result also showed that Piperacillin/ Tazobactum and 
Cefperazone/Sulbactum had essential sensitivity towards Klebsiella species and 
Escherichia coli. 
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During the entire study, Polymyxin antibiotics showed sensitivity to all 
microorganisms. Cephalosporins showed low sensitivity towards gram negative 
microorganisms. But Flouroquinolones showed fully resistant patterns in 
Klebsiella species,E.coli, S.aureus and Pseudomonas. 
Amino glycoside (Amikacin) and Tetracyclin antibiotics are shown fairly 
good sensitivity towards all the gram-positive and gram-negative organisms 
involved in this study. Carbapenems like Imipenem and Ertapenem showed 
appreciable activity against gram-negative organisms in the entire study. 
Glycopeptide antibiotics such as Vancomycin and Teicoplanin showed appreciable 
sensitivity towards gram-positive organisms. However, since the sample size was 
inadequate, so the result could not be consider as accurate. 
Furthermore, our data suggest that the most effective antimicrobials remain 
for gram-positive organism such as Staphylococcus aureus in this study is 
Doxycyclin followed by Vancomycin and for gram-negative species such as 
Klebsiella species, Escherichia coli, Pseudomonas aeruginosa is Carbapenams 
followed by Piperacillin/Tazobactum. 
The study emphasizes that, clinically significant Nosocomial infection is a 
serious consequence of a wide variety of initially localized infections, including 
those of the urinary tract, respiratory tract, surgical sites and indwelling devices 
such as central lines. Treatment is often urgent and may have to be undertaken 
without definitive identification of the organisms involved and their antimicrobial 
susceptibilities. These inadequate empirical therapy of nosocomial infections is 
associated with adverse outcomes, including increased mortality. Antimicrobial 
resistance is a common reason for these inadequate therapy. In this situation, 
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knowledge of the most likely causative organisms and their expected resistance 
patterns can increase the probability of selecting an effective antimicrobial for 
empirical treatment. Timely surveillance studies can contribute reliable 
information to this knowledge base at national or regional level, although 
knowledge of local variations, at the level of individual hospital units etc. 
Appropriate surveillance is also essential to monitor resistance trends and 
help to identify the factors that may be driving them. These surveillance systems 
make use of a network of laboratory-generated antibiograms that are constructed 
on the basis of the cumulative antimicrobial susceptibility data from each hospital. 
Antibiograms are currently used to estimate the impact of changes in antibiotic 
usage and to determine infection control strategies and antibiotic usage policies. 
Furthermore, antibiograms are often taken into account to define a rational 
selection of an empirical antimicrobial therapy for treating patients with hospital-
acquired infections.  
This study conveys that the major reason for antibiotic resistance is the 
inappropriate use of antibiotics due to lack of uniform policies and disregard for 
hospital infection control practices. So it is the time to think, plan and formulate a 
strong antibiotic policy to address this present scenario. Hence in the near future 
itself antibiotic prescribing guidelines have to be prepared and implemented for 
Nososcomial infections. Otherwise, empirical therapies will be ineffective which 
will in turn lead to widespread abuse of broad spectrum antibiotics which will 
ultimately result in further increase of resistance. 
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